CareDx closes $171M sale of Lab Products to Eurobio, acquires Naveris for $162M+

CareDx, Inc.

Sale of Lab Products business to Eurobio closed June 30 for $171.2M cash, sharpening focus on U.S. testing services.
Acquisition of Naveris closed July 1 for $161.8M cash plus up to $100M earnout based on 2026-2027 revenue milestones.
Naveris' NavDx test is the only Medicare-covered MRD test for HPV+ head/neck and anal cancers; 130K+ tests reported.
Naveris generated ~$35M revenue in 2025, more than doubling YoY; ADLT reimbursement rate of $1,800 per test.
Combined estimated U.S. addressable market exceeds $12B across transplant, specialty oncology, and cell therapy.

Featured in Daily 8-K Digest

Selected #4 for 2026-07-07. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.